Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3470 Molecular Imaging Tumor Volume of Somatostatin Receptor (MITVSSR) on 68Ga-DOTATATE PET/CT, dosimetry and predictors of overall survival and response in unresectable neuroendocrine neoplasms treated with Peptide Receptor Radionuclide Therapy (PRRT)

Introduction: PRRT delivers targeted radionuclide therapy to Neuroendocrine Neoplasms (NENs) with high SSR expression.

Conference:

Presenting Author:

Authors: Alipour R, Jackson P, Callahan J, Bressel M, Hogg A,

Keywords: PRRT, dosimetry, survival, response,

#3451 Peptide Receptor Radionuclide Therapy (PRRT) and impact on quality of life in patients with neuroendocrine neoplasms: An international multi-centre study

Introduction: Neuroendocrine neoplasms (NENs) affect health-related quality of life (HRQOL) due to tumor burden, hormone-secretory symptoms, and treatment-related side effects.

Conference:

Presenting Author: Kong G

Authors: Kong G, Corsini N, Hogg A, Mercurio J, Bailey D,

Keywords: PRRT, HRQOL, Neuroendocrine neoplasm, Multi-centre study, QLQ-C30,

#3161 Phase 1 trial of PARP inhibitor combined with 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastatic neuroendocrine tumor - PARLuNET

Introduction: 177Lu-DOTA-Octreotate (177Lu-DOTATATE) is an effective treatment for patients with grade 1 and 2 NET. However, strategies are required to optimize treatment efficacy and outcomes. Combining a DNA-repair modifying agent could further enhance radiation efficacy. Pre-clinical data supports that a PARP inhibitor (PARPi) combined with PRRT significantly enhances NET cell death and animal survival compared to 177Lu-DOTATATE alone. This combination strategy aims to enhance radiation efficacy from PRRT.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kong G

Authors: Kong G, Hatzimihalis A, Hogg A, Bressel M, Hicks R,

Keywords: PRRT, PARP inhibitor, combination therapy, NET, pancreatic, phase 1,

#2901 Data is Power - Registry Experience at an ENETS COE

Introduction: The collection of anonymised data for patients with neuroendocrine tumours is necessary for the ongoing improvement of patient care and research/clinical trials.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hogg A

Authors: Hogg A, Stell A, Marusic P, Sinnott R, Cummins M,

Keywords: PROMS, mobile phone app, registry,